IMiDs for myeloma induced renal impairment
Open Access
- 26 October 2018
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (84) , 35476-35477
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II TrialJournal of Clinical Oncology, 2018
- Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010)Blood, 2014
- Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II studyHaematologica, 2014
- Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123(12):1826-1832.Blood, 2014
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyBlood, 2014
- The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myelomaLeukemia, 2012
- The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal functionCancer, 2010
- Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failureEuropean Journal of Haematology, 2004